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SUMMARY. The process of preparing endoscopic esophageal adenocarcinoma samples for next-generation
DNA/RNA sequencing is poorly described. Therefore, we assessed the feasibility and pitfalls of preparing esophageal
adenocarcinoma endoscopic biopsies toward DNA/RNA samples suitable for next-generation sequencing. In this
prospective study, four tumor biopsy samples were collected from consecutive esophageal cancer patients during
esophagogastroduodenoscopy and fresh-frozen in liquid nitrogen. DNA and RNA were isolated from samples with a
tumor percentage of at least 50%. For next-generation sequencing, double-stranded DNA (dsDNA) is required and
high-quality RNA preferred. The quantity dsDNA and RNA quantity and quality were assessed with the Nanodrop
2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). Biopsy samples of 69 consecutive patients with esophageal adenocarcinoma were included.
In five patients (7%), the tumor percentage was less than 50% in all four biopsies. Using a protocol allowing
simultaneous DNA and RNA isolation, the median dsDNA yield was 2.4 μg (range 0.1–12.0 μg) and the median
RNA yield was 0.5 μg (range 0.01–2.05 μg). The median RNA integrity number of samples that were fresh-frozen
within 30 minutes after sampling was 6.7 (range 4.2–8.9) compared with 2.5 (1.8–4.5) for samples that were
fresh-frozen after 2 hours. The results from this study show that obtaining dsDNA and RNA for next-generation
sequencing from endoscopic esophageal adenocarcinoma samples is feasible. Tumor percentage and dsDNA/RNA
yield and quality emphasize the need for sampling multiple biopsies and minimizing the delay before fresh-freezing.
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INTRODUCTION
The last decade of biomedical science is characterized
by major technological advances. The increasing
availability of tissue-based microarrays and, more
recently, sequencing technology enable us to analyze
tissue genome and transcriptome with unprecedented
speed at relatively low costs.1 Because of these
advances, it is likely that large-scale DNA and RNA
analyses of tumor samples will be incorporated not
only in future research but also in clinical practice.
High-quality preserved tissue in combination with
well-documented clinical data is considered a prereq-
uisite for the generation of reliable data. Earlier papers
on tissue collection and biobanking have mainly
focused on the methodology of biobanking using sur-
gical resection specimens.2–5 Currently, the standard
potentially curative treatment of esophageal cancer
consists of neoadjuvant chemo(radio)therapy fol-
lowed by surgical resection.6,7 The collection of
untreated tumor samples is therefore limited to endo-
scopic biopsies. The small size of these biopsies poses a
challenge in obtaining sufficient amounts of high-
quality DNA and RNA. Several studies on gene
expression profiling of esophageal cancer using endo-
scopic biopsies have been published.8–12 However,
detailed descriptions of sample collection and
work-up are lacking in current literature. Such
descriptions are invaluable in guiding biobanking
initiatives and future experimental study design in
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esophageal cancer. The aim of the current study was to
assess the feasibility of preparing untreated esopha-
geal adenocarcinoma endoscopic biopsies toward
DNA and RNA samples suitable for next-generation
sequencing. This information is important as it can
help in guiding future and ongoing biobanking initia-
tives that are essential for studies aimed at genomically
characterizing this often-lethal cancer.
METHODS
Patients
In September 2008, our prospective study started with
collecting endoscopic biopsies of esophageal cancer
for genomic profiling. Patients with esophageal cancer
who presented with potentially curable disease were
eligible for the study. In the current study, only
patients with esophageal adenocarcinoma who were
planned to undergo neoadjuvant chemoradiotherapy
followed by surgical resection were included. Clinical
patient data were collected in a prospectively main-
tained database. Biopsy samples were collected after
oral and written informed consent was obtained. The
study was approved by the ethical committee.
Sample collection
During endoscopy, four tumor biopsy samples and
two biopsy samples from normal esophageal tissue
were obtained using a 2.2-mm biopsy forceps. The
samples were placed on gauze with NaCl 0.9% to
prevent dehydration, and preferably immediately
transported to the pathology department and fresh-
frozen in liquid nitrogen. The time of fresh-freezing
was recorded. All samples were stored at −80°C until
further processing.
Tumor percentage
The tumor percentage in each biopsy sample was
estimated by the following method: using a cryostat
at −20°C up to 20 slides of 30-μm thickness were
prepared and immediately stored at −80°C. Before
and after these 20 slides, an 8-μm slide was prepared
for hematoxylin and eosin staining. A pathologist
scored the tumor percentage in both 8-μm slides. The
average of the tumor percentage in both 8-μm slides
was considered the tumor percentage in the biopsy
sample. When the average tumor percentage was
below 50%, a second biopsy sample was processed,
and so on until a sample with a tumor percentage of
at least 50% was found. In biopsy samples with a
clear separation of normal and tumor-rich areas,
manual microdissection was performed to enrich the
tumor percentage. We did not perform laser capture
microdissection in this study.
DNA and RNA extraction and quality control
Because of the limited availability of tumor tissue,
DNA and RNA were simultaneously extracted from
every sample using the DNA/RNA AllPrep microkit
(Qiagen, Basel, Switzerland), according to the
manufacturer’s instructions. After extraction, DNA
samples were kept at 4°C and RNA samples were
stored at −80°C. DNA and RNA quantity was first
measured with the Nanodrop 2000 spectrophoto-
meter (Thermo Fisher Scientific, Waltham, MA,
USA). When the total RNA yield was less than 0.1 μg,
a second biopsy sample with a tumor percentage ≥50%
– if available – was used for RNA isolation with the
Qiagen RNeasy kit. Double-stranded DNA (dsDNA)
quantity and RNA quality was analyzed on the
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA,
USA). Currently, the most common method to assess
RNA integrity is by calculating the RNA integrity
number (RIN) from an electrophoretic trace. This
number varies between 1 (totally degraded RNA) and
10 (intact RNA). DNA and RNA input recommenda-
tions for next-generation sequencing differ between
protocols. dsDNA and RNA with little to no signs of
degradation (RIN > 8) are preferably used. For the
purpose of this study, the cut-off for a sufficient quan-
tity of high-quality DNA was set at a minimum of
1.0 μg of dsDNA. For RNA, this was at least 0.1 μg of
RNA with a RIN of at least 8. These numbers are
according to the requirements suggested in the
Illumina Truseq (Illumina, San Diego, CA, USA)
DNA and RNA sequencing library preparation
protocols.
Statistics
Differences in the median RIN between samples with
a different interval between sampling and fresh-
freezing were compared using the Kruskal–Wallis
test. All tests were two sided and a P-value < 0.05 was
considered statistically significant. SPSS statistical




Between September 2008 and May 2013, endoscopic
biopsy samples of 118 patients with esophageal cancer
who were referred for potentially curative treatment
were obtained according to the study protocol.
Twenty-eight patients with squamous cell carcinoma,
one patient with a neuroendocrine carcinoma and one
patient with an undifferentiated carcinoma were
excluded from the analysis. Of the remaining 88
patients diagnosed with adenocarcinoma, 10 patients
appeared to have metastatic disease during further
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diagnostic work-up and were treated with palliative
therapy. Seven patients were treated with definitive
chemoradiotherapy. One patient did not complete
chemoradiotherapy because of severe pulmonary
complications. In another patient, fresh-frozen mate-
rial had to be used for routine diagnostics. This left a
homogeneous cohort of 69 patients with esophageal
adenocarcinoma included in this study (Fig. 1). Of
these, nine (13%) were staged as cT2 and 60 (87%) as
cT3. Forty-nine (71%) of 69 patients had clinically
lymph node-positive disease. Twenty-one (30%) of 69
tumors were moderately differentiated and 29 (42%)
had a poor differentiation grade. In 14 (20%) of 69
tumors, the differentiation grade was unknown.
Tumor percentage
In 33 of 69 study patients (48%), more than one
tumor biopsy was required to obtain a sample with a
tumor percentage of at least 50%. In total, 129 biopsy
samples were used in this study: one biopsy was suf-
ficient for a tumor percentage >50% in 36 patients
(52%), a second biopsy was necessary in 16 patients
(23%), a third biopsy in seven patients (10%), and a
fourth biopsy in five patients (7%). In the endoscopic
biopsies of another five patients (7%), the tumor per-
centage was below 50% in all four samples. This left
64 samples that were suitable for subsequent DNA
and RNA isolation. Low tumor percentages were
mainly caused by normal epithelium, stromal tissue,
and/or leukocyte infiltration (Fig. 2A–D).
DNA/RNA quantity and quality
DNA and RNA quantity and quality results are sum-
marized in Table 1. First, a protocol was used that
allows isolation of both DNA and RNA from the
same sample (DNA/RNA AllPrep kit). In 57 of 64
samples (89%), the dsDNA quantity was at least
1.0 μg. In 18 of 64 samples (28%), RNA quantity was
lower than 0.1 μg. In 12 of these patients, a second
biopsy with a tumor percentage ≥50% was available.
In all these samples, more than 0.1 μg of RNA was
isolated with the RNeasy kit. The median RIN of all
58 RNA samples with a yield higher than 0.1 μg was
5.5 (range 1.8–8.9). Only 4 of 58 samples (7%) had a
RIN above 8. Thirty samples (52%) had a RIN
between 5 and 8, and in 24 samples (41%), the RIN
 Biopsy samples from 69 paents with esophageal 
adenocarcinoma selected for work-up
Tumor percentage ≥ 50%
(n = 64)
dsDNA ≥ 1.0 μg 
(n = 57)
RNA ≥ 0.1 μg
(n = 58)
RNA < 0.1 μg
(n = 6)
Tumor percentage < 50% in all available 
biopsies (n = 5)
dsDNA < 1.0 μg
(n = 7)
Fig. 1 Work-up of endoscopic biopsy samples from patients with esophageal adenocarcinoma who were treated with
chemoradiotherapy followed by surgery.
dsDNA, double-stranded DNA.
Table 1 DNA and RNA quantity and quality using the Qiagen
Allprep and RNeasy kits
DNA/RNA
AllPrep kit RNEasy kit†
(n = 64) (n = 12)
dsDNA
Concentration (ng/μL)§ 47 (2–240)‡ –
Total yield (μg)§ 2.4 (0.1–12.0)‡ –
Number (%) of samples
with yield > 1.0 μg§
57 (89%) –
RNA
Concentration (ng/μL)¶ 33 (1–808)‡ 75 (25–194)‡
Total yield (μg)¶ 0.5 (0.01–11.0)‡ 3.1 (1.2–9.7)‡
Number (%) of samples
with yield > 0.1 μg
46 (72%) 12 (100%)
RIN 5.5 (2.3–8.4)‡ 5.7 (1.8–8.9)‡
†From 12 patients in whom the RNA yield was less than 0.1 μg
using the AllPrep kit, a second biopsy with sufficient tumor was
available for RNA isolation using the RNEasy kit. ‡Median
(range). §Concentration and total yield according to the Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). ¶Concentration
and total yield according to the Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA). dsDNA, double-
stranded DNA; RIN, RNA integrity number.
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was lower than 5. From 52 samples, the time interval
between biopsy sampling and fresh-freezing was
available. RIN values decreased significantly with
increased time periods before fresh-freezing of biopsy
samples (Fig. 3). In 18 of 24 samples (75%) frozen
after 1 hour, the RIN was below 5.
DISCUSSION
The current study results provide a detailed descrip-
tion of our prospective biobanking efforts with
untreated esophageal cancer endoscopic biopsies.
Several important issues were encountered that should
be taken into account in future biobanking projects.
Low tumor percentages in biopsy samples led to a
considerable sample loss. In 5 of 69 (7%) patients, the
tumor percentage was below 50% in all (four) endo-
scopic biopsy samples obtained for research purposes.
In 57 of 64 samples (89%) with a tumor percentage of
at least 50%, more than 1.0 μg of dsDNA could be
isolated. Sufficient RNA (at least 0.1 μg) was isolated
from 58 of 64 samples (91%). A time delay between
sampling and fresh-freezing of biopsies had a negative
effect on RNA quality: in 18 of 24 samples (75%)
frozen after 1 hour, RNA showed considerable degra-
dation (RIN lower than 5).
Tumor percentage
When studying DNA from tumor tissue, these
samples are preferably representative with an
adequate number of tumor cells. Lower tumor per-
centages can significantly decrease the sensitivity of
detecting genomic aberrations by diluting tumor
DNA with DNA from normal tissue. This is exem-
A B
C D
Fig. 2 Hematoxylin and eosin slides from study biopsies with normal stroma and leukocyte infiltration compromising the tumor
percentage. (A, B; magnified): tumor biopsy with a considerable amount of normal stroma. (C, D; magnified): tumor biopsy with a
considerable amount of leukocyte infiltration compromising the tumor percentage.
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plified in a study with colon cancer samples in which
the ability to correctly identify KRAS mutations was
diminished with a decreasing tumor percentage.13 In
contrast, the effect of normal tissue ‘contamination’
on RNA gene expression profiling has been ques-
tioned. In most studies aimed to develop prognostic
gene expression signatures, only samples with a high
(>50%) percentage of tumor cells are allowed.14,15
However, in a study validating the 70-gene breast
cancer prognosis signature, the minimum tumor per-
centage was decreased to 30% as this figure also gen-
erated a reliable read-out.5 Consequently, no definite
thresholds are defined but most in most studies
samples with a minimum tumor percentage between
50 and 70% are used. Because of the introduction of
neoadjuvant treatment strategies, untreated esopha-
geal cancer tissue samples can only be obtained by
endoscopic biopsy. The acquisition of representative
tumor samples during endoscopy is more challenging
than that of adequate material from surgical resec-
tion specimens, but methods to estimate the tumor
percentage in esophageal biopsy samples vary widely
in current literature. In some studies, the tumor per-
centage was assessed on each biopsy sample used for
downstream applications,11,12 while in other studies
an adjacent biopsy sample was used.8–10 Our results
underline the need to assess the tumor percentage in
all biopsy samples used for downstream applications.
Low tumor percentages in biopsy samples led to a
considerable sample loss, emphasizing the need to
obtain multiple biopsies. In the current study, we
included patients with locally advanced esophageal
adenocarcinoma. The majority had a clinical tumor
stage of T3, with a moderate to poor tumor differen-
tiation. Even in these advanced tumors, obtaining a
representative biopsy sample was a challenge. In
recent years, biomarker studies and the development
of risk stratification models have increasingly focused
on Barrett’s associated pre-cancerous and early
esophageal adenocarcinoma.16 It is likely that obtain-
ing representative samples from these lesions is even
more challenging. Moreover, given the inter- and
intra-observer variability in correctly grading these
lesions (e.g. low-grade vs. high-grade dysplasia), the
role of an expert pathologist in biobanking project
with these samples becomes even more important.17
DNA/RNA quantity and quality
Assessing the quantity and quality of DNA/RNA is
pivotal in determining which protocol is used for pre-
paring the samples for sequencing. Currently, intact
dsDNA is needed for next-generation sequencing.
For RNA sequencing, protocols allowing the input of
minute quantities of degraded RNA have been devel-
oped, but sequencing results are still better with pro-
tocols requiring intact RNA.18 Because archival
formalin-fixed paraffin-embedded tissue usually
yields degraded DNA and RNA, fresh-frozen speci-
mens are preferred. In the current study, the majority
Time interval between sampling and fresh freezing


























(n = 15) (n = 13) (n = 15) (n = 9)
Fig. 3 Effect of a time interval between sampling and fresh-freezing on RNA quality of endoscopic biopsies of esophageal
adenocarcinoma. Numbers above box plots display the median (range) RNA integrity number. RIN, RNA integrity number.
*Kruskal–Wallis test.
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of samples yielded a sufficient quantity (>1.0 μg)
intact dsDNA. In contrast, RNA was degraded in a
large number of samples. Although it is generally
believed that fresh tissue should be frozen as quickly
as possible to prevent RNA degradation, there are
some conflicting results in current literature. In two
studies with resection specimens from colon and pan-
creatic cancer, a prolonged time period before fresh-
freezing did not adversely affect RNA quality.3,4
These results are in contrast to a study by Hong
et al., in which colorectal carcinoma biopsy samples
obtained from resection specimens were left at 4°C
for 10–90 minutes before fresh-freezing in liquid
nitrogen.19 The mean RIN for samples frozen after 10
minutes was 7.5 compared with 4.2 for samples
frozen after 90 minutes. Moreover, 18 of 20 samples
(90%) of samples frozen after 90 minutes had a RIN
<7. In a study by Maher et al., 25 endoscopic biopsy
samples from esophageal cancer patients were col-
lected for gene expression analysis.10 They report that
in 13 of 25 samples (52%), RNA of sufficient quantity
and quality was obtained for microarray analysis. In
this study, biopsy samples were immediately placed
in an RNA protective agent (RNAlater) before
fresh-freezing. Taken together, a short time interval
between tissue sampling and fresh-freezing seems
especially important for small endoscopic biopsy
samples.
The use of different protocols for DNA and RNA
isolation adds complexity to the interpretation of the
current literature on biobanking. Protocols allowing
simultaneous isolation of DNA and RNA greatly
increase the efficient use of valuable tissue, but the
performance regarding DNA and RNA yield and
quality in comparison with dedicated kits has been
questioned. In a study by Mathieson et al., the
AllPrep kit was compared with two dedicated kits for
DNA (Puregene) and RNA (RNeasy) isolation.20 The
dedicated DNA isolation kit performed better than
the AllPrep kit in yield and quality, but RNA yield
and quality were comparable between the AllPrep
and RNeasy kit. In the current study, the RNeasy kit
was used when the total RNA yield with the AllPrep
kit was <0.1 μg and another biopsy sample with an
adequate tumor percentage was available. The RNA
yield from these samples was higher, but RNA
quality still differed considerably. It was not the goal
of the current study to compare the efficiency of dif-
ferent kits and protocols and these results need to be
interpreted with caution. Still, it is possible that the
results of DNA and RNA isolation can be improved
when dedicated kits are used, with the use of more
tissue as a likely trade-off.
Concluding remarks
In conclusion, the results from this study show that
obtaining high-quality DNA and RNA from endo-
scopic esophageal adenocarcinoma samples is fea-
sible, but requires thorough logistical planning. Both
the tumor percentage in biopsy samples and DNA/
RNA yield and quality emphasize the need for sam-
pling multiple biopsies and minimizing the time delay
before fresh-freezing in the biobanking process of
esophageal adenocarcinoma.
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